Riding the First Wave: Wegovy® and Zepbound® 🏄 GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacy 🌊 The next waves might not be as colossal, but they …
Continue reading “The Next Wave of Obesity Drugs: Opportunities and Risks for Investors 🌊”
Press releases regarding first quarter results have been issued from diabetes competitors Novo Nordisk, Eli Lilly, Sanofi and others. Four of the main antidiabetic drug types manufactured by these pharmaceutical companies are insulin, GLP-1 receptor agonists, SGLT2 inhibitors (gliflozins) and DPP4 inhibitors (gliptins). The development in each of the four drug categories is covered in …
Continue reading “Diabetes developments in the first quarter of 2019”